Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study

British Journal of Cancer

Volumn 103, Issue 3, 2010, Pages 291-296

  Henry, N L ^a   Pchejetski, D ^b   A'Hern, R ^c   Nguyen, A T ^d   Charles, P ^e   Waxman, J ^b   Li, L ^d   Storniolo, A M ^f   Hayes, D F ^a   Flockhart, D A ^d   Stearns, V ^g   Stebbing, J ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f INDIANA UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

aromatase inhibitor; arthralgia; breast cancer; cytokine

Indexed keywords

AROMATASE INHIBITOR; EXEMESTANE; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LETROZOLE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CASE-CONTROL STUDIES; CYTOKINES; ESTROGENS; FEMALE; HUMANS; INFLAMMATION; MIDDLE AGED; MUSCULOSKELETAL DISEASES; POSTMENOPAUSE; SYNDROME; TAMOXIFEN; TAXOIDS;

EID: 77955051102     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605768     Document Type: Article

References (35)

1. Azria D, Lamy PJ, Belkacemi Y, Roux C, Gourgou S, Ozsahin M, Zaman K, Llacer Moscardo C, Lemanski C, Gutowski M, Bonneterre J, Romieu G, Gligorov J (2006) Letrozole-induced arthralgia is not consistent with an autoimmune disease resembling Sjogren's syndrome: preliminary results of a multicentric prospective trial. Breast Cancer Res Treat 100(Suppl 1): S25
2. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23: 5138-5147
3. Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, Cuvillier O (2006) Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20: 95-102
4. Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P (2007) Brief communication: rituximab in HIV-associated multicentric Castle-man disease. Ann Intern Med 147: 836-839 (Pubitemid 351664423)
5. Bower M, Veraitch O, Szydlo R, Charles P, Kelleher P, Gazzard B, Nelson M, Stebbing J (2009) Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood 113: 4521-4524
6. Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545
7. Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30: 167-178
8. Burstein HJ, Winer EP (2007) Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 25: 3797-3799
9. Carlsten H (2005) Immune responses and bone loss: the estrogen connection. Immunol Rev 208: 194-206
10. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907-916
11. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25: 486-492
12. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369: 559-570
13. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25: 3877-3883
14. Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9: 1143-1148
15. Donnellan PP, Douglas SL, Cameron DA, Leonard RC (2001) Aromatase inhibitors and arthralgia. J Clin Oncol 19: 2767
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
17. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509
18. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45-53
19. Gabay C (2006) Interleukin-6 and chronic inflammation. Arthritis Res Ther 8(Suppl 2): S3
20. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20: 751-757
21. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97: 1262-1271
22. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ (2008a) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111: 365-372
23. Henry NL, Giles JT, Stearns V (2008b) Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park) 22: 1401-1408
24. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455-462
25. Laroche M, Borg S, Lassoued S, De Lafontan B, Roche H (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's syndrome. J Rheumatol 34: 2259-2263
26. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, Milstien S, Kohama T, Spiegel S (2000) Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 275: 19513-19520
27. Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer Jr CE, Costantino JP, Wolmark N (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 26: 1965-1971
28. Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P (2008) Prospective Study to Assess Short-Term Intra-Articular and Tenosynovial Changes in the Aromatase Inhibitor-Associated Arthralgia Syndrome. J Clin Oncol 26: 3147-3152
29. Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 1822
30. Pfeilschifter J, Koditz R, Pfohl M, Schatz H (2002) Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23: 90-119
31. Sommer C, Kress M (2004) Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 361: 184-187
32. Stebbing J, Ngan S, Ibrahim H, Charles P, Nelson M, Kelleher P, Naresh KN, Bower M (2008) The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease. Clin Exp Immunol 154: 399-405
33. Straub RH (2007) The complex role of estrogens in inflammation. Endocr Rev 28: 521-574
34. Sukocheva O, Wadham C, Xia P (2009) Role of sphingolipids in the cytoplasmic signaling of estrogens. Steroids 74: 562-567
35. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23: 619-629